EPZM - エピザイム （Epizyme Inc.）EPZMのニュース
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology 2022/08/12 15:35:00 Business Wire
PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close. As part of the trans
Epizyme: Q2 Earnings Insights 2022/08/09 12:56:57 Benzinga
Epizyme (NASDAQ: EPZM ) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Epizyme beat estimated earnings by 41.67%, reporting an EPS of $-0.21 versus an … Full story available on Benzinga.com
Epizyme GAAP EPS of -$0.21, revenue of $27.5M 2022/08/09 12:29:07 Seeking Alpha
Epizyme press release (NASDAQ:EPZM): Q2 GAAP EPS of -$0.21.Revenue of $27.5M (+111.4% Y/Y).
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update 2022/08/09 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. “I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product revenue, we are continuing to advance several of our ta
Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance 2022/08/05 09:51:32 Seeking Alpha
Ipsen (IPSEY) (IPSEF) extended the expiration date for the tender offer to acquire cancer drug maker Epizyme (EPZM) to Aug. 11, from Aug
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology 2022/08/12 15:35:00 Business Wire
PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at deal close. As part of the trans
Epizyme: Q2 Earnings Insights 2022/08/09 12:56:57 Benzinga
Epizyme (NASDAQ: EPZM ) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here''s what investors need to know about the announcement. Earnings Epizyme beat estimated earnings by 41.67%, reporting an EPS of $-0.21 versus an … Full story available on Benzinga.com
Epizyme GAAP EPS of -$0.21, revenue of $27.5M 2022/08/09 12:29:07 Seeking Alpha
Epizyme press release (NASDAQ:EPZM): Q2 GAAP EPS of -$0.21.Revenue of $27.5M (+111.4% Y/Y).
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update 2022/08/09 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. “I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product revenue, we are continuing to advance several of our ta
Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance 2022/08/05 09:51:32 Seeking Alpha
Ipsen (IPSEY) (IPSEF) extended the expiration date for the tender offer to acquire cancer drug maker Epizyme (EPZM) to Aug. 11, from Aug
Epizyme Q1 2022 Earnings Preview 2022/05/09 16:10:33 Seeking Alpha
Epizyme (EPZM) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open.The consensus EPS Estimate is -$0.35 (+49.3% Y/Y) and the consensus Revenue Estimate…
Epizyme Announces Date of First Quarter 2022 Financial Results 2022/05/03 11:00:00 Business Wire
Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer
Analysts Predict Epizyme Inc. (NASDAQ: EPZM) To Loss -1288.89% From Current Levels. 2022/04/19 15:00:00 Stocks Register
The trading price of Epizyme Inc. (NASDAQ:EPZM) closed lower on Monday, April 18, closing at $0.72, -6.03% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7048 and … Analysts Predict Epizyme Inc. (NASDAQ: EPZM) To Loss -1288.89% From Current Levels. Read More »
Epizyme Inc. (NASDAQ: EPZM): Stock Plunge On The Way? 2022/04/18 14:00:00 Stocks Register
The trading price of Epizyme Inc. (NASDAQ:EPZM) closed lower on Thursday, April 14, closing at $0.76, -6.35% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.7352 and … Epizyme Inc. (NASDAQ: EPZM): Stock Plunge On The Way? Read More »